NCT05349617View on ClinicalTrials.gov

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

413

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

June 19, 2023

Study Completion Date

August 8, 2023

Conditions
Chikungunya Virus
Interventions
BIOLOGICAL

CHIKV VLP/adjuvant

PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant

BIOLOGICAL

Placebo

Placebo is comprised of formulation buffer

Trial Locations (10)

14609

Rochester Clinical Research, Inc., Rochester

29405

Coastal Carolina Research Center, North Charleston

33014

Panax Clinical Research, Miami Lakes

33173

Suncoast Research Associates, LLC, Miami

33705

Global Clinical Research Professionals (GCP), St. Petersburg

53095

Spaulding Clinical, West Bend

64114

AMR Kansas City, Kansas City

77065

DM Clinical Research CyFair, Houston

77375

DM Clinical Research Tomball, Tomball

78249

BHFC Research, San Antonio

Sponsors

Lead Sponsor

Bavarian Nordic

Collaborators (1)

Emergent BioSolutions
All Listed Sponsors
collaborator

Emergent BioSolutions

INDUSTRY

lead

Bavarian Nordic

INDUSTRY